Dr. Ningning Cheng | Cancer Research | Best Researcher Award
Attending Physician, Shanghai General Hospital, China
Dr. Ningning Cheng, Ph.D., is an accomplished Attending Physician in the Department of Radiation Oncology at Shanghai General Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, China. She obtained her Ph.D. in Oncology from Tongji University, Shanghai (2012–2015) and her M.Sc. in Oncology from Qingdao University, Qingdao (2009–2012). Her research is primarily focused on radiotherapy dose escalation, PET/CT-guided radiation treatment planning, combined chemoradiotherapy in esophageal and lung cancers, and tumor resistance mechanisms, aiming to enhance precision oncology and patient outcomes. With a deep commitment to integrating clinical oncology with advanced imaging technologies, Dr. Ningning Cheng has made significant contributions to translational cancer research, particularly through studies on PET/CT-directed radiotherapy dose escalation, exemplified by her recent publication in Radiotherapy and Oncology (2025), which improved treatment efficacy in locally advanced esophageal cancer. Professionally, she has served as an Attending Physician (2019–present) and previously as a Physician in the Department of Medical Oncology (2015–2018) at Shanghai General Hospital, demonstrating leadership in both clinical and academic oncology. Her research portfolio includes 14 peer-reviewed publications, accumulating 712 citations with an h-index of 10, reflecting a growing international impact. Dr. Ningning Cheng has participated in several multidisciplinary and institutional research projects funded by national and hospital-level grants. She has been recognized for her outstanding contributions to oncology through institutional awards and honors for research excellence, and she actively engages in peer-review and professional societies dedicated to cancer treatment and radiation medicine. Her long-term vision centers on advancing precision radiotherapy and molecular imaging–based cancer care to improve therapeutic outcomes and global standards in radiation oncology. Through her research, mentorship, and clinical expertise, Dr. Ningning Cheng continues to make meaningful contributions to science, society, and the advancement of personalized cancer therapy.
Featured Publications
1. Cheng, N., Chen, Z., Chen, Y., Hu, Y., Wang, Z., Chen, X., Liu, Q., & Chen, T. (2025). 18F-FDG PET/CT directed radiotherapy dose escalation in locally advanced esophageal cancer (LAEC): A phase I study. Radiotherapy and Oncology, 213, 111176.
2. Sun, Z., Cheng, N., Cai, Z., Ying, Z., Liu, H., Chen, X., Zeng, H., Yin, M., Liu, H., Tan, S., Zhou, X., Zhao, X., & Chen, F. (2025). Multifunctional microsphere dressings via metal ligand bonding engineering for infectious wound healing. Journal of Materials Science & Technology, 219, 158–172.
3. Cheng, N., Liu, Y., Zhao, G., Xu, Y., Zhang, T., Chen, Y., Yan, G., Hu, Y., Yao, S., Wang, Z., Wang, C., Chen, Z., Hu, Z., Liu, D., & Chen, T. (2020). Phase I trial of intensity-modulated hyperfractionated radiotherapy boost with concurrent chemotherapy immediately following standard chemoradiotherapy in patients primarily with advanced intra-thoracic/cervical esophageal squamous cell carcinomas. International Journal of Radiation Oncology, Biology, Physics, 106(2), 340–348.
4. Wang, Q., Li, X., Ren, S., Su, C., Li, C., Li, W., Yu, J., Cheng, N., & Zhou, C. (2020). HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. Lung Cancer, 147, 99–105.